| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1/II data readout example | LX2020 PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM) | Phase 1 | — | Gene Therapies | Cardiovascular System | ||
Phase 1/II data readout example | LX2020 PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM) | Phase 1 | — | Gene Therapies | Cardiovascular System | ||
Phase 1/II data readout example | LX2020 PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM) | Phase 1 | — | Gene Therapies | Cardiovascular System |
Recent Updates
Recently added Catalysts
Lexeo Therapeutics, Inc.$4.92
-0.12 (-2.38%)
D 34Pipeline Score Overvalued Biotech · Commercial
Market Cap
401.25 M
EPS
-1.45
P/E Ratio
-
Value Trade
2.84 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
15.70 M
Operating CF
-21.14 M
Total Assets
250.36 M
Total Liabilities
18.86 M
Equity
231.50 M
D/E Ratio
12,345
-5.55 %
Week
-19.53 %
1 Month
-17.85 %
3 Month
-42.26 %
6 Month
-46.21 %
5 Year
-46.21 %
All Time
Cash Data
Cash Position
193.04 M
Monthly Burn
7.05 M
Runway
26.2 mo
Burn Trend
StableSEC Filing
May 11, 2026
Overview
Volume
762.80 K
52 Week Range
2.51 - 10.99
% held by Insiders
21.46 %
% held by Institutions
100.16 %
Enterprise Value
215.57 M
Total Shares
78.53 M
Short %
17.97 %
Float Shares
76.64 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D34
Pipeline Score $43M
Pipeline ValueOvervalued
Valuation Signal1
Drugs Scored0.4x
rNPV / MCap Top 45%
Micro Cap (rank 499 of 905)
Percentile RankLexeo Therapeutics, Inc. faces pipeline headwinds (34/100), with $107M risk-adjusted pipeline value, led by LX1001 in Alzheimer Disease (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LX1001 Monoclonal antibody | Alzheimer Disease | Phase 1 | NCT05400330 | 10% | $107M | ACTIVE NOT_RECRUITING | 25 | STALLED | D (23) | Nov 1, 2028 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
LX2006 | Friedreich ataxia | Phase 1/2 | 2025-07-08 | |||
LX2006 | Friedreich ataxia | Phase 1/2 | 2025-07-08 | |||
LX2006 | Friedreich ataxia | Phase 1/2 | 2025-07-08 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LXEO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Lexeo Therapeutics, Inc. (LXEO) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
LXEO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LXEO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LXEO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LXEO Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
LXEO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
LXEOLexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia
Lexeo Therapeutics announced the publication of Phase I/II data for LX2006 in Friedreich ataxia in JAMA Cardiology. The results indicate that LX2006 is generally well tolerated and shows early signs of efficacy, with improvements in cardiac and neurologic measures. The pivotal SUNRISE-FA 2 study is set to initiate in Q2 2026, with topline data expected in 2H 2027.
Read more →LXEOLexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia
Lexeo Therapeutics has announced the finalization of the SUNRISE-FA 2 pivotal trial protocol for its gene therapy candidate LX2006, targeting Friedreich ataxia cardiomyopathy. The trial will enroll participants aged 16 and older and aims for a BLA submission under the accelerated approval pathway in 2028. The study design incorporates FDA feedback and aims to address significant unmet needs in patients with this condition.
Read more →LXEOLexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
Lexeo Therapeutics, a clinical stage genetic medicine company, will participate in the 2026 RBC Capital Markets Global Healthcare Conference. The event is scheduled for May 19, 2026, at 2:35 p.m. ET in New York. The presentation will be available via live webcast and later as a replay on their website.
Read more →LXEOLexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights
Lexeo Therapeutics reported its Q1 2026 financial results, highlighting advancements in its clinical pipeline, particularly for LX2006 in Friedreich Ataxia and LX2020 in PKP2 Arrhythmogenic Cardiomyopathy. The company is preparing to initiate the SUNRISE-FA 2 pivotal trial pending FDA feedback. Financially, Lexeo maintains a strong position with $227.6 million in cash, expected to fund operations into 2028.
Read more →LXEOLexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
Lexeo Therapeutics will present new data at the 29th ASGCT Annual Meeting, showcasing advancements in its cardiac gene therapy programs and AAV manufacturing. Key presentations include a novel TNNI3 gene therapy and updates on the LX2006 candidate for Friedreich ataxia. The event provides an opportunity to demonstrate the company's scientific progress to industry peers.
Read more →LXEOLexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026 following Type B me
Lexeo Therapeutics reported its fourth quarter and full year 2025 financial results, highlighting positive developments in its LX2006 and LX2020 clinical programs. The company has submitted the pivotal trial protocol for LX2006 to the FDA and plans to initiate the SUNRISE-FA 2 trial in the first half of 2026. During the ACC Annual Meeting, promising efficacy and safety results were presented for both programs, underscoring Lexeo's progress in addressing cardiovascular diseases. The company's financials reflect a reduced net loss compared to the previous year alongside a robust cash position to support ongoing operations.
Read more →LXEOLexeo Therapeutics to Participate in the Leerink Global Healthcare Conference
Lexeo Therapeutics, a clinical stage genetic medicine company, will participate in the Leerink Global Healthcare Conference on March 10, 2026. The event will feature a fireside chat and will be webcast live, allowing broader access to stakeholders. Lexeo is dedicated to developing innovative treatments for cardiovascular diseases, including specific therapies for conditions like Friedreich ataxia cardiomyopathy.
Read more →LXEOLexeo Therapeutics to Participate in Upcoming Investor Conferences in February
Lexeo Therapeutics announced its participation in two investor conferences in February 2026. The company will engage in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on February 12 and at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26. These events highlight Lexeo's commitment to advancing genetic medicine for cardiovascular diseases.
Read more →LXEOLexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics
Lexeo Therapeutics has announced key leadership appointments, including Dr. Narinder Bhalla as Chief Medical Officer, to bolster its expertise in cardiovascular medicine. The company also updated its strategic partnership with Perceptive Xontogeny and venBio Partners to develop novel RNA therapies for genetic cardiac diseases. These moves aim to enhance Lexeo's clinical and commercial objectives.
Read more →LXEOLexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy LX2020 generally well tolerated across ten participants with no clinically signi
Lexeo Therapeutics announced promising interim data from its HEROIC-PKP2 Phase I/II clinical trial for LX2020, a treatment for PKP2-associated arrhythmogenic cardiomyopathy. The therapy was well tolerated among ten participants, showing significant increases in PKP2 protein expression, with mean improvements in arrhythmia burden for most participants. Despite some elevated liver function tests and a serious adverse event, the data highlight the potential of LX2020 in addressing the underlying causes of cardiac dysfunction. Lexeo aims to continue advancing LX2020's development and plans regulatory engagement in the coming year.
Read more →LXEOLexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy
Lexeo Therapeutics has announced a research collaboration with Johnson & Johnson aimed at exploring localized cardiac delivery methods for adeno associated viral (AAV) gene therapy. This partnership seeks to advance gene therapy for cardiovascular diseases by leveraging Impella heart pump technology to direct delivery to the heart. The goal is to reduce AAV dosage requirements and improve safety while enhancing clinical efficacy. Lexeo is focused on developing innovative treatments for genetic causes of cardiovascular conditions.
Read more →LXEOLexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Lexeo Therapeutics, a clinical stage genetic medicine company, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. CEO R. Nolan Townsend will discuss the company's innovative approaches to treating cardiovascular diseases. The event will be available for live streaming and later replay on their website.
Read more →LXEOLexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum
Lexeo Therapeutics, a clinical stage genetic medicine company, announced a virtual event focused on managing PKP2-Associated Arrhythmogenic Cardiomyopathy. The event, featuring Dr. Victoria Parikh, will take place during the 22nd Global Cardiovascular Clinical Trialists Forum on December 9th. This initiative highlights Lexeo's commitment to innovative treatments for cardiovascular diseases and involves experts in the field.
Read more →LXEOLexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights
Lexeo Therapeutics reported its Q3 2025 financial results, highlighting positive interim data for LX2006 in treating Friedreich ataxia. The FDA is open to data pooling from ongoing studies to support a Biologics License Application. The company completed enrollment for the LX2020 HEROIC-PKP2 Phase I/II trial and secured $154 million in equity financing to support its cardiac pipeline.
Read more →LXEOLexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares in the Public Offering
Lexeo Therapeutics has successfully closed its underwritten public offering and concurrent private placement, raising around $153.8 million. The public offering included the sale of 17,968,750 shares at $8.00 each, with additional proceeds from prefunded warrants. This funding will support Lexeo's development of genetic therapies for cardiovascular diseases.
Read more →LXEOLexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement
Lexeo Therapeutics has successfully priced its public offering and concurrent private placement, aiming to raise around $135 million. The company will sell 15,625,000 shares at $8.00 each, with an additional option for underwriters to purchase more shares. The transactions are expected to close by October 20, 2025, subject to customary conditions.
Read more →LXEOLexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
Lexeo Therapeutics has initiated a public offering and private placement of common stock and pre-funded warrants. The offering aims to raise capital for its innovative treatments targeting cardiovascular diseases. The company has engaged several financial institutions for the offering, which is subject to market conditions and other customary factors.
Read more →LXEOLexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy
Lexeo Therapeutics has announced positive interim clinical data for LX2006, a gene therapy for Friedreich ataxia cardiomyopathy, showing significant improvements in cardiac and neurologic measures. The FDA is open to pooling ongoing Phase I/II study data to support a Biologics License Application for accelerated approval. The company aims to initiate a pivotal study in the first half of 2026.
Read more →LXEOForward Looking Statements This presentation contains “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, statements regarding Lexeo's expectations
Lexeo Therapeutics announced advancements in its FDA discussions concerning the accelerated approval pathway for its product LX2006, aimed at treating Friedreich ataxia cardiomyopathy. Interim clinical data revealed significant improvements in cardiac and neurologic functions among participants. The FDA is receptive to including data from ongoing Phase I/II studies in its review, which may expedite the submission process for a Biologics License Application (BLA). These developments highlight the potential of LX2006 to address urgent treatment needs in a condition with a high mortality rate due to cardiac complications.
Read more →LXEOLexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights Breakthrough Therapy designation granted for LX2006 based on interim data from Phase I/II trials demonstrating clinically meanin
Lexeo Therapeutics reported significant operational progress and financial results for Q2 2025. The company received FDA Breakthrough Therapy designation for its gene therapy candidate LX2006, supported by promising interim trial data. Additionally, Lexeo secured $80 million in equity financing to bolster its clinical programs and announced a strategic partnership to enhance its product offerings in genetic cardiac therapies. Leadership changes were also announced, with Louis Tamayo appointed as CFO to guide financial strategy.
Read more →LXEOLexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia
Lexeo Therapeutics announced that the FDA has granted Breakthrough Therapy designation for LX2006, based on promising interim clinical data showing improvements in cardiac and neurologic measures for Friedreich ataxia. The designation aims to accelerate development timelines and enhance patient access to this potential treatment. Additionally, LX2006 is part of the FDA's CMC Development and Readiness Pilot program.
Read more →LXEOLexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics
Lexeo Therapeutics has announced a partnership with Perceptive Xontogeny Venture Funds and venBio Partners to develop RNA-based therapies for genetic cardiac diseases. The collaboration includes an investment of up to $40 million, which will fund a new entity focused on advancing non-viral RNA delivery methods. Lexeo will contribute its expertise and preclinical intellectual property, aiming to address unmet needs in cardiovascular treatment.
Read more →LXEOLexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases
Lexeo Therapeutics has announced an $80 million equity financing to support its development of genetic medicines for cardiovascular diseases. The financing, led by Frazier Life Sciences and Janus Henderson Investors, will fund operations through a potential efficacy readout for LX2006 in Friedreich ataxia cardiomyopathy in 2027. The private placement is expected to close on May 28, 2025.
Read more →LXEOLexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights Announced positive interim data for LX2006 from Phase 1/2 studies in Friederich ataxia (FA) cardiomyopathy; frataxin expression a
Lexeo Therapeutics announced positive interim data for LX2006 from ongoing Phase 1/2 studies treating Friedrich ataxia cardiomyopathy, demonstrating improved frataxin expression and cardiac metrics. The company plans to initiate a registrational study by early 2026 and start enrollment in a related natural history study in Q2 2025. Despite increased net losses and staff reductions, Lexeo maintains a strong cash position to support its clinical programs into 2027.
Read more →LXEOLexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
Lexeo Therapeutics, a clinical stage genetic medicine company, announced that it will present new data on its AAV manufacturing approach at the upcoming 28th Annual Meeting of the ASGCT in May 2025. The data highlight the company's capabilities in producing high-quality AAV with improved efficiency and scalability. This advancement is expected to enhance the progress of Lexeo's clinical-stage gene therapy programs aimed at treating various cardiovascular diseases.
Read more →LXEOLexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study
Lexeo Therapeutics announced positive interim data for LX2006, a treatment for Friedreich ataxia cardiomyopathy, demonstrating significant improvements in cardiac biomarkers and functional measures across all studied cohorts. The interim results indicate a 25% mean reduction in left ventricular mass index (LVMI) and a notable increase in frataxin expression. The findings support the advancement of LX2006 to a planned registrational study, scheduled for early 2026, aimed at further assessing its efficacy. The treatment has been generally well tolerated, with no severe adverse events reported to date.
Read more →LXEOLexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights Additional alignment with FDA on LX2006 planned pivotal study including protein expression co-primary endpoint: ba
Lexeo Therapeutics has reported its financial results and operational highlights for Q4 and the full year of 2024. The company achieved further regulatory alignment with the FDA on its pivotal study for LX2006, while also announcing positive interim data from the LX2020 HEROIC-PKP2 trial. The firm maintains a solid cash position, sufficient to support operations into 2027. However, it faced increased net loss and rising expenses, which may pose financial challenges ahead.
Read more →LXEOLexeo Therapeutics Corporate Overview
Lexeo Therapeutics recently provided an overview highlighting its focus on developing innovative gene therapies for serious cardiac diseases, specifically Friedreich Ataxia Cardiomyopathy (LX2006) and PKP2-ACM (LX2020). The company aims to address major unmet treatment needs with potential best-in-class therapies. Forward-looking statements reveal potential risks regarding regulatory approvals and clinical outcomes, but initial data show optimistic trends in cardiac expression and safety. Lexeo's advancements are supported by favorable changes in the regulatory landscape and technological improvements in treatment delivery.
Read more →LXEOLexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Lexeo Therapeutics, a clinical stage genetic medicine company, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. CEO R. Nolan Townsend will deliver the presentation in San Francisco, California. The company focuses on innovative treatments for genetically defined cardiovascular diseases and related conditions. A live webcast of the event will be available, with a replay following the presentation.
Read more →LXEOLexeo Therapeutics Appoints Kyle Rasback as Chief Financial Officer NEW YORK –
Lexeo Therapeutics has appointed Dr. Kyle Rasback as Chief Financial Officer, effective immediately. Dr. Rasback comes with a solid background in life sciences and financial management, having previously served in leadership roles at Zentalis Pharmaceuticals and Eventide Asset Management. Lexeo's CEO expressed excitement about Dr. Rasback joining the team, emphasizing the importance of his expertise as the company advances its gene therapy programs. Lexeo is preparing for pivotal studies and has several meaningful catalysts on the horizon.
Read more →LXEOLexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer
Lexeo Therapeutics has appointed Dr. Kyle Rasbach as Chief Financial Officer, effective immediately. Dr. Rasbach brings significant experience in life sciences, previously serving as Chief Business Officer at Zentalis Pharmaceuticals and succeeding in various financial and management roles. His appointment is seen as pivotal as the company prepares for crucial advancements in its gene therapy programs. CEO R. Nolan Townsend highlighted his expertise as instrumental in supporting Lexeo's growth and mission to develop treatments for genetic conditions.
Read more →LXEOLexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated app
Lexeo Therapeutics provided updates on its cardiac portfolio and reported its financial results for Q3 2024, highlighting significant advancements in the development of LX2006 for Friedreich ataxia cardiomyopathy. The company reached an alignment with the FDA on accelerated approval pathways and received RMAT designation for LX2006, which may facilitate expedited development. Enrollment has completed for the SUNRISE-FA trial, and interim data from LX1001 for Alzheimer's showed promising results. Despite these advancements, the financial report indicated increased expenses and a net loss compared to the prior year.
Read more →LXEOLexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD)
Lexeo Therapeutics announced positive interim results for LX1001, a gene therapy aimed at treating APOE4-associated Alzheimer's disease. The Phase 1/2 study revealed favorable safety and tolerability, with neuroprotective APOE2 expression increasing in a dose-dependent manner across participants. Additionally, notable reductions in tau biomarkers were recorded, suggesting potential therapeutic benefits. The company is set to engage with the FDA regarding regulatory interactions and development plans for LX1001 in 2025.
Read more →LXEOLexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference
Lexeo Therapeutics is set to present interim data from its Phase 1/2 trial of LX1001 at the upcoming Clinical Trials on Alzheimer’s Disease conference. The trial targets APOE4 homozygous patients, who have limited treatment options for Alzheimer’s disease. The data will provide insights on safety and biomarker measures across different dosing cohorts and include findings relevant to efficacy. This initiative represents a significant step in addressing the underlying genetic causes of Alzheimer’s for this particular patient group.
Read more →LXEOForward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, statements regarding Lexeo's expectations
Lexeo Therapeutics has outlined its forward-looking statements regarding its gene therapy product candidates, focusing on their ongoing clinical trials and the anticipated benefits. The company is addressing genetic cardiovascular diseases and exploring treatments for the APOE4 genetic variant associated with Alzheimer's disease. Interim results from its cardiomyopathy trials suggest notable reductions in cardiac measurements. However, the firm also acknowledges several risks, including potential discrepancies between trial phases and possible regulatory delays.
Read more →LXEOLexeo Therapeutics to Participate in Upcoming Investor Conferences
Lexeo Therapeutics, a clinical stage genetic medicine company, has announced its participation in several upcoming investor conferences. These include major events such as the H.C. Wainwright 26th Annual Global Investment Conference and the Baird 2024 Global Healthcare Conference. Through these presentations and webcasts, Lexeo aims to communicate its advancements in treating genetically defined cardiovascular diseases and Alzheimer’s disease associated with APOE4. The company is leveraging its pipeline of innovative programs to attract investor interest.
Read more →LXEOLexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights Announced positive interim data from Phase 1/2 studies in Friedreich ataxia (FA) cardiomyopathy, which showed LX2006 was well to
Lexeo Therapeutics reported its financial results and operational highlights for Q2 2024, showcasing encouraging interim data from its LX2006 therapy for Friedreich ataxia cardiomyopathy. The interim results indicated that the treatment was well tolerated and showed promising efficacy across various cardiac measures. The company also initiated formal discussions with the FDA regarding surrogate endpoints for an upcoming registrational study. Financially, Lexeo reported a net loss of $21.2 million but maintains a robust cash position projected to fund operations into 2027.
Read more →LXEOLexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy Achieved mean reduction in left ventricular mass index (LVMI) of 11.4% at 12 months an
Lexeo Therapeutics announced positive interim data from its Phase 1/2 clinical trial of LX2006 for Friedreich ataxia cardiomyopathy, showing a significant reduction in left ventricular mass index (LVMI) at 12 and 18 months. The treatment was well tolerated, with no serious adverse events reported. Improved cardiac biomarkers were recorded, and increased frataxin expression was observed in participants. These results suggest a promising potential for LX2006 in treating FA cardiomyopathy, a severe condition currently lacking approved therapies.
Read more →LXEOLexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024
Lexeo Therapeutics, Inc. announced an investor webcast scheduled for July 15, 2024, to provide interim clinical data on LX2006 for the treatment of Friedreich ataxia cardiomyopathy. The webcast will summarize data from the ongoing SUNRISE-FA Phase 1/2 clinical trial and a related study by Weill Cornell Medicine. LX2006 is a gene therapy being evaluated for its safety and efficacy in treating FA cardiomyopathy. The presentation will also cover future steps for the program.
Read more →LXEOLexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors NEW YORK –
Lexeo Therapeutics has appointed Tim Van Hauwermeiren, co-founder and CEO of argenx SE, to its Board of Directors. Van Hauwermeiren brings over two decades of experience in the life sciences sector and is recognized for building successful biotech firms. His expertise will be critical as Lexeo advances its pipeline and aims for growth in treating cardiovascular diseases and Alzheimer's. The move signals a strategic step for Lexeo as it looks to leverage his background to enhance its clinical and commercial endeavors.
Read more →LXEOLexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights Closed an oversubscribed $95 million equity financing in March with Q1 2024 cash balance of $195.1 million at quarter-end, expect
Lexeo Therapeutics reported strong financial results for Q1 2024, including a successful $95 million equity financing and a cash balance of $195.1 million. The company completed an in-license agreement with Cornell University to bolster data for its LX2006 program and anticipates interim clinical data in mid-2024. Additionally, Lexeo's Phase 1/2 trial of LX2020 is actively recruiting patients with results expected in the second half of the year. Despite a net loss increase, the company remains optimistic about its prospects and upcoming milestones.
Read more →LXEOLexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy Lexeo Therapeutics gains intellectual property rights including current and future
Lexeo Therapeutics has announced a license agreement with Cornell University to expedite the development of LX2006, an investigational gene therapy for Friedreich ataxia cardiomyopathy. This agreement includes the acquisition of existing and future clinical data from an ongoing Phase 1A trial, supporting regulatory discussions. Currently, a total of 11 participants have undergone treatment, with no serious adverse events reported. An interim readout of data from the combined studies is anticipated in mid-2024, potentially doubling the number of evaluable patients.
Read more →LXEOLexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich's Ataxia Cardiomyopathy NEW YORK –
Lexeo Therapeutics has received FDA Fast Track designation for its gene therapy candidate LX2006, aimed at treating Friedreich's ataxia cardiomyopathy. The therapy seeks to deliver a functional frataxin gene to improve mitochondrial function in heart cells. Current clinical trials are evaluating its safety and efficacy, with positive preclinical results showing improvements in cardiac function. This designation highlights the urgent need for effective treatments for FA cardiomyopathy, as no approved options currently exist.
Read more →LXEOLexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing
Lexeo Therapeutics has successfully closed an oversubscribed private placement, raising approximately $95 million by selling 6,278,905 shares at $15.13 each. The financing was co-led by prominent firms and included participation from both new and existing investors. The funds will be utilized to advance clinical stage programs and support general corporate purposes, providing financial stability for operations until 2027. Lexeo is focused on developing treatments for genetically defined cardiovascular diseases and Alzheimer's disease associated with APOE4.
Read more →LXEOLexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights Lexeo announces $95.0M equity financing, which in addition to 2023 year-end cash and cash equivalents of $121.5M,
Lexeo Therapeutics reported its financial results for Q4 and the full year of 2023, announcing a $95 million equity financing and presenting initial positive data from the SUNRISE-FA trial for LX2006, which showed increased frataxin levels in patients. The company aims to fund operations through 2027 and is on track with clinical milestones for its key therapies, including LX2020 and LX1001. Despite positive developments, Lexeo faces challenges with rising R&D and G&A expenses, alongside a net loss reported in Q4. The anticipated interim clinical data readouts in mid-2024 aim to provide further insights into the progress of their treatments.
Read more →LXEOLexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing
Lexeo Therapeutics has announced an oversubscribed equity financing of $95 million to fund its ongoing clinical programs, primarily targeting genetically defined cardiovascular diseases and Alzheimer's disease. The private placement involved the issuance of over 6 million shares at $15.13 per share, set to close on March 13, 2024. Investors in the financing include well-known firms such as RA Capital Management and Novo Holdings A/S. The proceeds will bolster Lexeo's operational capabilities and extend its financial runway through 2027.
Read more →LXEOLexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments NEW YORK –
Lexeo Therapeutics has announced new executive appointments aimed at strengthening its leadership in clinical development. Key figures include Sandi See Tai as Chief Development Officer, Eric Adler as Chief Medical Officer & Head of Research, and Rajiv Patni as Senior Advisor. These appointments are expected to leverage the extensive experience of the executives in rare diseases and gene therapy, enhancing the company’s progress toward late-stage clinical trials for its pipeline focusing on genetically defined cardiovascular diseases and Alzheimer’s.
Read more →LXEOLexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Lexeo Therapeutics, a clinical-stage genetic medicine company, is set to present at the 42nd Annual J.P. Morgan Healthcare Conference scheduled for January 10, 2024. CEO R. Nolan Townsend will deliver the presentation in San Francisco, showcasing the company's innovative approach to treating genetically defined cardiovascular diseases and Alzheimer's disease associated with APOE4. The event will be accessible via a live webcast on the company's website, with a replay available afterward. Lexeo's focus on applying pioneering science aims to significantly advance treatment options in their fields of expertise.
Read more →LXEOLexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM) NEW YORK –
Lexeo Therapeutics has announced that their gene therapy candidate, LX2020, has received both Fast Track and Orphan Drug designations from the FDA for the treatment of PKP2 arrhythmogenic cardiomyopathy. This disease, linked to PKP2 gene mutations, has no approved treatments, making LX2020 a potential breakthrough. The upcoming HEROIC-PKP2 clinical trial will assess the safety and efficacy of this AAV-based therapy in patients. The designations will facilitate development and regulatory review of this novel therapy aimed at a serious cardiovascular condition.
Read more →LXEOLexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights Completed enrollment of the LEAD Phase 1/2 clinical trial of LX1001 for the treatment of APOE4-associated Alzheimer's disease Rec
Lexeo Therapeutics reported its third quarter 2023 financial results and highlighted key operational milestones, including the completion of enrollment in the LEAD Phase 1/2 clinical trial of LX1001 for treating APOE4-associated Alzheimer's disease. The company successfully received clearance for its LX2006 clinical trial application in Canada and activated its first clinical trial site outside the U.S. Additionally, Lexeo raised $111.5 million through an IPO to support its operational runway into late 2025. The firm is poised to provide additional clinical data readouts in 2024.
Read more →LXEOLexeo Therapeutics Announces Pricing of Initial Public Offering
Lexeo Therapeutics, a clinical-stage genetic medicine company, has announced the pricing of its initial public offering (IPO) at $11.00 per share, aiming to raise approximately $100 million. The IPO will consist of 9,090,910 shares, with trading expected to start on Nasdaq under the ticker LXEO on November 3, 2023. The offering is anticipated to close on November 7, 2023, subject to standard conditions. Despite the positive outlook, there are inherent risks related to the closing conditions and the developmental challenges of genetic therapies.
Read more →LXEOLEXEO Therapeutics Announces Strategic Investment from Sarepta Therapeutics to Support Development of LEXEO’s Cardiovascular Gene Therapies
LEXEO Therapeutics has announced a strategic investment from Sarepta Therapeutics to enhance its development of adeno-associated virus (AAV) gene therapies aimed at cardiovascular diseases. This partnership will explore the creation of novel gene therapy candidates targeting various cardiovascular conditions that currently have significant unmet medical needs. Notably, LEXEO's pipeline has the potential to address the root causes of these diseases in approximately one million patients in the United States. While the financial specifics of the investment remain undisclosed, both companies express optimism about the collaboration's potential to transform treatment approaches for genetic cardiovascular diseases.
Read more →LXEOLEXEO Therapeutics Announces FDA Clearance of IND for LX2020, an AAV-based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy
LEXEO Therapeutics has received FDA clearance for its IND application for LX2020, an AAV-based gene therapy aimed at treating PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM). The therapy aims to deliver a functional PKP2 gene to cardiac muscle, potentially addressing the root causes of the disease. Preliminary studies have shown promise in restoring cardiac function in mouse models. A Phase 1/2 trial is planned to evaluate the safety and efficacy of LX2020 in human subjects, marking a significant step toward developing effective treatments for this serious condition.
Read more →LXEOLEXEO Therapeutics Announces Completion of First Cohort and Dosing in Second Cohort in SUNRISE-FA, a Phase 1/2 Clinical Trial of LX2006 for the Treatment of Friedreich’s Ataxia Cardiomyopathy
LEXEO Therapeutics has completed the first dosing cohort and initiated the second in its Phase 1/2 SUNRISE-FA clinical trial for LX2006, a gene therapy targeting Friedreich’s ataxia cardiomyopathy. The first cohort showed no unexpected adverse events, prompting further investigation. Initial data, including biomarkers related to cardiac function, is expected by mid-2024. LX2006 aims to address the urgent need for effective treatments in this debilitating condition.
Read more →LXEOLEXEO Therapeutics Announces Data Presentations at the 26th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
LEXEO Therapeutics has announced the presentation of new data supporting its gene therapy programs at the upcoming ASGCT Annual Meeting. The company aims to address challenging diseases, including arrhythmogenic right ventricular cardiomyopathy and Alzheimer's disease. With eight abstracts selected, the findings underscore their commitment to developing AAV-based therapies. The presentations will showcase research advancements and potentially significant impacts on patient care.
Read more →LXEOLEXEO Therapeutics Appoints Micah Zajic as Chief Financial Officer and Paula H. J. Cholmondeley as Board of Directors Audit Committee Chair
LEXEO Therapeutics has announced the appointments of Micah Zajic as Chief Financial Officer and Paula H.J. Cholmondeley as Audit Committee Chair. Zajic, with nearly 20 years of experience in biotech and finance, is expected to leverage his strategic insights to guide LEXEO through a growth phase, particularly in advancing gene therapies for cardiovascular and CNS diseases. Cholmondeley, an accomplished finance leader with extensive audit committee experience, is set to enhance LEXEO's corporate governance as the company expands its leadership team.
Read more →LXEOLEXEO Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
LEXEO Therapeutics, a clinical-stage biotech company, will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023. The CEO, R. Nolan Townsend, will share insights into the company's pipeline of adeno-associated virus-based gene therapy candidates targeting cardiovascular and CNS diseases. The firm collaborates with leading academic institutions to foster innovation in genetic medicine and disease treatment.
Read more →LXEOLEXEO Therapeutics Bolsters Cardiac Gene Therapy Leadership with New Executive Appointment and Formation of Scientific Advisory Board
Eric Adler, M.D., joins LEXEO as Chief Scientific Officer New Scientific Advisory Board comprised of molecular cardiology, cardiovascular imaging, cardiac gene-editing, and RNA biology experts NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- LEXEO Therapeutics, Inc. (LEXEO), a clin
Read more →LXEOLEXEO Therapeutics to Present Clinical and Preclinical Data at Upcoming Scientific Conferences
- Presentations at the International Congress for Ataxia Research (ICAR) will feature LEXEO’s LX2006 gene therapy program for Friedreich’s ataxia (FA) cardiomyopathy - - A presentation at American Heart Association Scientific Sessions to feature preclinical data from LEXEO’s LX2
Read more →LXEOLEXEO Therapeutics Receives Orphan Drug Designation for LX1004 from European Commission
– LX1004 is an adeno-associated virus (AAV) based gene therapy for the treatment of CLN2 Batten disease – – In a completed Phase 1/2 clinical trial, LX1004 demonstrated a favorable safety profile and showed statistically significant reduction in rate of decline compared to natur
Read more →LXEOLEXEO Therapeutics to Present New Clinical Data from its Investigational Gene Therapy LX1001 for APOE4-Associated Alzheimer’s Disease at the 29th European Society of Gene & Cell Therapy Annual Meeting
NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- LEXEO Therapeutics, Inc. (LEXEO), a clinical-stage biotech company advancing a pipeline of adeno-associated virus (AAV)-based gene therapy candidates for cardiovascular and central nervous system (CNS) diseases, today announced new clin
Read more →LXEOLEXEO Therapeutics Announces Data Presentations at the 25th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
Preclinical studies support clinical development of pipeline programs, including novel gene therapies for the treatment of genetically defined cardiovascular and central nervous system diseases NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- LEXEO Therapeutics (LEXEO), a clinical-sta
Read more →LXEOLEXEO Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, March 21, 2022 (GLOBE NEWSWIRE) -- LEXEO Therapeutics (LEXEO), a clinical-stage gene therapy company advancing a deep and diverse pipeline of adeno-associated virus (AAV)-based gene therapy candidates for genetically defined cardiovascular and central nervous system (CN
Read more →LXEOLEXEO Therapeutics Announces Positive Initial Data from Ongoing Phase 1/2 Clinical Trial of AAV-based Gene Therapy Candidate LX1001 in Patients with Alzheimer’s Disease
– In the initial clinical data from low-dose cohort of the ongoing trial, we observed that LX1001 expressed the protective APOE2 protein in the CNS and decreased core Alzheimer’s disease-related biomarkers – – No serious adverse events reported to date, indicating an emerging fa
Read more →LXEOLEXEO Therapeutics Announces FDA Clearance of Investigational New Drug Application for LX2006, an AAV-based Gene Therapy Candidate for Friedreich’s Ataxia Cardiomyopathy
- Phase 1/2 clinical trial expected to initiate in mid-2022 - - LX2006 is the first clinical-stage program from LEXEO’s cardiovascular pipeline and the third clinical-stage gene therapy candidate across its pipeline - NEW YORK, Feb. 16, 2022 (GLOBE NEWSWIRE) -- LEXEO Therapeuti
Read more →LXEOLEXEO Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- LEXEO Therapeutics, a fully integrated clinical-stage gene therapy company advancing adeno-associated virus (AAV)-mediated treatments for genetic conditions, today announced that R. Nolan Townsend, Chief Executive Officer of LEXEO Thera
Read more →LXEOLEXEO Therapeutics and FUJIFILM Diosynth Biotechnologies Announce Collaboration to Support Development and Manufacturing of Gene Therapies for Genetic Diseases
NEW YORK, Oct. 13, 2021 (GLOBE NEWSWIRE) -- LEXEO Therapeutics, a fully integrated clinical-stage gene therapy company advancing adeno-associated virus (AAV)-mediated treatments for genetic conditions, and FUJIFILM Diosynth Biotechnologies, a world leading contract development an
Read more →LXEOLEXEO Therapeutics Closes $100 Million Series B Financing to Advance Clinical Stage Gene Therapy Pipeline and Enhance Preclinical Footprint
Financing led by D1 Capital Partners and Eventide Asset Management with participation from additional investors including returning Series A investors Proceeds to support continued preclinical pipeline development in rare cardiovascular diseases and the genetics of Alzheimer’s d
Read more →LXEOLEXEO Therapeutics Receives Rare Pediatric Disease Designation and Orphan Drug Designation for LX1004 for the Treatment of CLN2 Batten Disease
NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- LEXEO Therapeutics, a fully integrated clinical-stage gene therapy company advancing disease-modifying treatments for genetic conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Diseas
Read more →LXEOLEXEO Therapeutics Expands Cardiac Gene Therapy Pipeline with Acquisition of Stelios Therapeutics and its Gene Therapy Programs for Rare Cardiovascular Diseases
LEXEO obtains exclusive rights to three investigational AAV-mediated gene therapy programs for rare cardiac disorders, all of which have no existing disease-modifying treatments available Strategic acquisition expands LEXEO’s rare cardiac gene therapy pipeline making it one of t
Read more →LXEOLEXEO Therapeutics Receives Rare Pediatric Disease Designation and Orphan Drug Designation for LX2006 for the Treatment of Friedreich’s Ataxia
NEW YORK, June 30, 2021 (GLOBE NEWSWIRE) -- LEXEO Therapeutics, a clinical-stage gene therapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation and Orphan Drug designation to LX2006 for the treatment of Friedr
Read more →LXEOLEXEO Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy (ASGCT) 2021 Virtual Annual Meeting
Data evaluating intravenous delivery of the AAVrh.10 viral vector show effectiveness in providing high levels of gene transfer to the heart for the potential treatment of rare cardiac diseases Data on second generation investigational gene therapy demonstrate ability to silence
Read more →LXEOLEXEO Therapeutics Announces FDA Fast Track Designation Granted to LX1001 for the Treatment of APOE4 Associated Alzheimer’s Disease
LX1001 is the first investigational gene therapy being evaluated to address the underlying genetics of Alzheimer’s disease Initial Phase 1 clinical data expected in 2H 2021 NEW YORK, April 20, 2021 (GLOBE NEWSWIRE) -- LEXEO Therapeutics, a clinical-stage gene therapy company, t
Read more →LXEOLEXEO Therapeutics Strengthens Management Team with Key Appointments to Accelerate Development of Clinical-Stage Pipeline
NEW YORK, April 06, 2021 (GLOBE NEWSWIRE) -- LEXEO Therapeutics, a clinical-stage gene therapy company, today announced the continued expansion of its management team with the appointments of two seasoned executives leading critical business functions, including Paul McCormac, Ph
Read more →LXEOLEXEO Therapeutics Announces License Agreement and Consolidation of Comprehensive Pre-clinical Data Package to Support Cardiac Friedreich's Ataxia Gene Therapy Program (LX2006)
LEXEO completes license of all intellectual property rights and pre-clinical data associated with Adverum Biotechnologies’ investigational Friedreich’s ataxia program Pre-clinical research licensed from academic partners and data from Adverum’s program now consolidated to suppor
Read more →LXEOLEXEO Therapeutics Launches with $85 Million Series A Financing to Develop Gene Therapies for Rare and Non-Rare Monogenic Diseases
Rare disease and gene therapy industry veterans Steven Altschuler, M.D., R. Nolan Townsend and Jay Barth, M.D., team up with gene therapy pioneer Ronald Crystal, M.D., to launch fully integrated gene therapy company Financing led, structured and syndicated by Longitude Capital a
Read more →Competitive Position
How LXEO ranks across every disease it competes inCompetitive Position is a premium feature
See how LXEO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial